ORIGINAL ARTICLE   

Minerva Dental and Oral Science 2023 October;72(5):247-54

DOI: 10.23736/S2724-6329.23.04790-3

Copyright © 2023 EDIZIONI MINERVA MEDICA

language: English

Salivary microRNAs as innovative biomarkers for early diagnosis of oral diseases: a comparison of conventional cigarette smokers and tobacco heating system 2.2 users

Giuseppe MINERVINI ^{1, 2}, Aida METO ³, Luca FIORILLO ⁴, Rocco FRANCO ⁵ ✉, Fabrizio di FRANCESCO ², Marco CICCIÙ ⁴, Gabriele CERVINO ⁴

¹ Faculty of Dentistry, Alexandria University, Alexandria, Egypt; ² Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania “Luigi Vanvitelli”, Naples, Italy; ³ Department of Dentistry, Faculty of Dental Sciences, University of Aldent, Tirana, Albania; ⁴ Department of Biomedical and Dental Sciences, Morphological and Functional Images, University of Messina, Messina, Italy; ⁵ Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy

BACKGROUND: MicroRNAs (miRNAs) are considered valid prognostic and diagnostic biomarkers. The different miRNA expression profiles in cancer cells compared to normal cells make them potential biomarkers used for the early diagnosis of oral diseases. Following exposure to cigarette smoking, miRNA altered profile expression is associated with resistance mechanisms against anticancer therapies. Cellular models showed a reduced human gingival epithelium alteration after exposure to THS2.2 and a lower pathogenicity than 3R4F CS. The aim of the study was to compare the expression of saliva miRNA profile of THS2.2 and 3R4F CS users compared to patients not exposed to the risk factor and to identify and study the modulation of miRNAs associated with the development of oral diseases. In particular, we will focus on the analysis of a group of miRNAs know to be involved in the development of smoking-related diseases.
METHODS: The study will be performed in 18 months and dentists and biochemists will be involved in the different phases. To perform the study, healthy volunteers, including smokers of THS2.2 or 3R4F CS, will be enrolled.
RESULTS: The samples will be collected from 3 experimental groups, each consisting of 30 subjects: group 1 (no smoking subjects), group 2 (subjects exposed to THS2.2), group 3 (subjects exposed to 3R4F CS). The collection of the saliva sample will be conducted in a standardized way. Following the collection, saliva will be processed.
CONCLUSIONS: Previous studies have suggested that miRNAs are prognostic biomarkers for various smoking-related diseases. Based on the post-transcriptional regulation of some mRNAs connected to different oral pathologies, we expect a specific miRNA-mRNA interaction, which could be a starting point for the development of new possible diagnostic, therapeutic and prognostic approaches.

KEY WORDS: MicroRNAs; Smokers; Biomarkers; Tobacco products